---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-001679"
form_type: "8-K"
ticker: "CAMP"
cik: "0001736730"
company_name: "Camp4 Therapeutics Corp"
filed_at: "2025-01-07T23:59:59+00:00"
generated_at: "2026-05-28T08:47:34.852277+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Camp4 Therapeutics reports positive Phase 1 SAD safety data for CMP-CPS-001, enables MAD dose escalation

## Summary
- Phase 1 SAD portion completed: 48 healthy volunteers, 32 received CMP-CPS-001; no serious adverse events, no maximum tolerated dose reached.
- All treatment-emergent adverse events were Grade 1 or 2; most common: headache (6), nausea (4).
- Safety Review Committee approved dose escalation and initiation of MAD Cohort 3.
- Cash runway into Q2 2026; upcoming milestones: MAD data 2H'25, SYNGAP1 GLP tox studies in '25.
- Corporate slide deck highlights RAP platform, pipeline, and strategic collaboration; IPO completed October 2024.

## SEC filing metadata
- accession: 0001104659-25-001679
- form_type: 8-K
- ticker: CAMP
- cik: 0001736730
- company_name: Camp4 Therapeutics Corp
- filed_at: 2025-01-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/0001104659-25-001679-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1736730/000110465925001679/tm252128d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-001679
- JSON: https://secwatch.observer/filing/0001104659-25-001679.json
- Plain text: https://secwatch.observer/filing/0001104659-25-001679.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.